Sage Therapeutics, Inc.
Symbol: SAGE
NASDAQ
12.34
USDMarket price today
-1.4749
P/E Ratio
0.0371
PEG Ratio
742.65M
MRK Cap
- 0.00%
DIV Yield
Sage Therapeutics, Inc. (SAGE) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 753.2 | 1272.5 | 1742.3 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 682.2 | 1109.8 | 1448.1 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 83 | 13.7 | 18.5 | ||||||||||||
balance-sheet.row.inventory | 0 | 1.3 | -64.5 | -18.5 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 31.8 | 50.8 | 58.3 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 869.4 | 1272.5 | 1800.6 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 6.4 | 13.4 | 19.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 1.3 | 1.3 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 6.5 | 69.3 | 4.3 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 12.9 | 84 | 24.6 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 882.3 | 1356.4 | 1825.3 | ||||||||||||
balance-sheet.row.account-payables | 0 | 10.3 | 18.9 | 10.4 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 5.2 | 7.6 | 7.5 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 4.5 | 11 | ||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 67.3 | 72.7 | 67.3 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0 | 4.6 | 11.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 5.2 | 12.1 | 18.4 | ||||||||||||
balance-sheet.row.total-liab | 0 | 82.7 | 103.8 | 96.3 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | -2569.7 | -2028.2 | -1495.4 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -0.8 | -10.2 | -2.7 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 3370 | 3291 | 3227.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 799.5 | 1252.6 | 1729 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 882.3 | 1356.4 | 1825.3 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 799.5 | 1252.6 | 1729 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 682.2 | 1109.8 | 1448.1 | ||||||||||||
balance-sheet.row.total-debt | 0 | 5.2 | 12.1 | 18.4 | ||||||||||||
balance-sheet.row.net-debt | 0 | -65.8 | -150.6 | -275.8 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -541.5 | -532.8 | -457.9 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1.4 | 1.1 | 4.2 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 73.4 | 61.6 | 104.6 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -67.4 | 5.7 | -18.5 | ||||||||||||
cash-flows.row.account-receivables | 0 | -69.3 | 4.8 | -18.5 | ||||||||||||
cash-flows.row.inventory | 0 | 69.3 | -4.8 | 18.5 | ||||||||||||
cash-flows.row.account-payables | 0 | -8.5 | 8.4 | 6.7 | ||||||||||||
cash-flows.row.other-working-capital | 0 | -58.9 | -2.8 | -6.7 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | -6.5 | 4.4 | -10.6 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.6 | -0.9 | -0.4 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | -442.9 | -326.4 | 1002.1 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -594.7 | -881 | -1990.2 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 1038.1 | 1207.4 | 988.1 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 442.9 | 326.4 | -1002.1 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 442.9 | 325.4 | -1002.4 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -7 | -6.3 | -5.7 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 6.9 | 3.1 | 14.7 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.9 | 0 | -1.4 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -3.2 | -7.6 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 6.1 | 9.5 | 13.3 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6 | 3.1 | 13.3 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 540.6 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | -91.6 | -131.5 | -1367.3 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 72.3 | 164 | 295.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 164 | 295.5 | 1662.8 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | -540.6 | -460 | -378.2 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -0.6 | -0.9 | -0.4 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | -541.1 | -461 | -378.6 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 86.5 | 7.7 | 6.3 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 2.2 | 0.8 | 0.6 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 84.3 | 6.9 | 5.8 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | -0.4 | 0 | 0.1 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 630.8 | 553.9 | 466.7 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 632.9 | 554.7 | 467.2 | ||||||||||||
income-statement-row.row.interest-income | 0 | 38.7 | 14.2 | 2.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 14.2 | 0 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -33.8 | 14.2 | 3 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.4 | 0 | 0.1 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -33.8 | 14.2 | 3 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 14.2 | 0 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1.4 | 1.1 | 4.2 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | -579.8 | -547 | -460.9 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | -541.5 | -532.8 | -457.9 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | -5.4 | -29.5 | -7.1 | ||||||||||||
income-statement-row.row.net-income | 0 | -541.5 | -503.3 | -450.8 |
Frequently Asked Question
What is Sage Therapeutics, Inc. (SAGE) total assets?
Sage Therapeutics, Inc. (SAGE) total assets is 882277000.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 0.965.
What is company free cash flow?
The free cash flow is -7.068.
What is enterprise net profit margin?
The net profit margin is -5.525.
What is firm total revenue?
The total revenue is -5.946.
What is Sage Therapeutics, Inc. (SAGE) net profit (net income)?
The net profit (net income) is -541489000.000.
What is firm total debt?
The total debt is 5165000.000.
What is operating expences number?
The operating expences are 630759000.000.
What is company cash figure?
Enretprise cash is 0.000.